Yungan A. Tao

Department Of Head And Neck Surgery
Villejuif, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 126 publications

Postoperative nivolumab in high-risk head and neck cancer - Authors' reply.

Postoperative nivolumab in high-risk head and neck cancer - Authors' reply.

Journal: Lancet (London, England)

Published: July 16, 2026

Postoperative SBRT and Severe Late Toxic Effects in Early-Stage Oropharyngeal and Oral Cavity Cancers: The STEREOPOSTOP-GORTEC 2017-03 Nonrandomized Clinical Trial.

Postoperative SBRT and Severe Late Toxic Effects in Early-Stage Oropharyngeal and Oral Cavity Cancers: The STEREOPOSTOP-GORTEC 2017-03 Nonrandomized Clinical Trial.

Journal: JAMA network open

Published: February 03, 2026

Acute and long-term toxicity profiles and final oncologic outcomes in the phase III ARTFORCE trial.

Acute and long-term toxicity profiles and final oncologic outcomes in the phase III ARTFORCE trial.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: January 23, 2026

Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.

Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 22, 2026

AI-redesigned starting points and outcomes enhance protein evolution.

AI-redesigned starting points and outcomes enhance protein evolution.

Journal: Nature

Published: December 16, 2025

Estimation of accumulated dose to organs at risk in head and neck cancer patients treated with scheduled replanning and dose painting in the ARTFORCE trial.

Estimation of accumulated dose to organs at risk in head and neck cancer patients treated with scheduled replanning and dose painting in the ARTFORCE trial.

Journal: Physics and imaging in radiation oncology

Published: November 28, 2025

AI-guided redesign of laboratory-evolved reverse transcriptases enhances prime editing.

AI-guided redesign of laboratory-evolved reverse transcriptases enhances prime editing.

Journal: Nature biotechnology

Published: November 25, 2025

Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022-01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin.

Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022-01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: November 25, 2025

Efficient prime editing in vivo and in vitro using lipid nanoparticles.

Efficient prime editing in vivo and in vitro using lipid nanoparticles.

Journal: Nature nanotechnology

Published: October 23, 2025

Directed evolution of small RNA-stabilizing motifs that improve prime-editing efficiency.

Directed evolution of small RNA-stabilizing motifs that improve prime-editing efficiency.

Journal: Nature biotechnology

Published: October 11, 2025

An international placebo-controlled randomized multicenter trial of nimorazole with accelerated chemo-radiotherapy for locally advanced HPV-negative squamous cell carcinoma of the head and neck (HNSCC).

An international placebo-controlled randomized multicenter trial of nimorazole with accelerated chemo-radiotherapy for locally advanced HPV-negative squamous cell carcinoma of the head and neck (HNSCC).

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: September 14, 2025

Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study.

Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 03, 2025

Showing 1-12 of 126

Last Updated: 09/26/2026